Search research articles
Contact Us
Filters
Showing results (121-130 of 168) with videos related to
Page
of 17
Sort By:
Anti-Cancer Drugs
|
January 3, 2020
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)
Anne Rodallec, Guillaume Sicard, Sarah Giacometti, et al.
Cancer Research
|
September 14, 2014
Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice
Niklas Hartung, Séverine Mollard, Dominique Barbolosi, et al.
Bulletin Du Cancer
|
August 15, 2018
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]
Florian Lemaitre, Françoise Goirand, Manon Launay, et al.
Hematological Oncology
|
March 15, 2025
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs
Erwann Collomb, Laurent Bourguignon, Antoine Tichadou, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
June 19, 2014
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment
Godefridus J Peters, Richard J Honeywell, Marie Maulandi, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 28, 2021
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study
Clémence Marin, Nihel Khoudour, Aurélien Millet, et al.
Cancer Chemotherapy and Pharmacology
|
November 13, 2023
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
Mourad Hamimed, Raynier Devillier, Pierre-Jean Weiller, et al.
Cancer Chemotherapy and Pharmacology
|
December 25, 2008
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile
Cedric Mercier, Charlotte Dupuis, Aurore Blesius, et al.
Clinical and Translational Science
|
February 15, 2020
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer
Clémence Marin, Anis Krache, Chloé Palmaro, et al.
Pharmacogenomics
|
September 6, 2019
Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency
Crescent C Gbeto, Sylvie Quaranta, Roxane Mari, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 168) with videos related to
Sort By:
Page
of 17
Anti-Cancer Drugs
|
January 3, 2020
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)
Anne Rodallec, Guillaume Sicard, Sarah Giacometti, et al.
Cancer Research
|
September 14, 2014
Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice
Niklas Hartung, Séverine Mollard, Dominique Barbolosi, et al.
Bulletin Du Cancer
|
August 15, 2018
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]
Florian Lemaitre, Françoise Goirand, Manon Launay, et al.
Hematological Oncology
|
March 15, 2025
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs
Erwann Collomb, Laurent Bourguignon, Antoine Tichadou, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
June 19, 2014
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment
Godefridus J Peters, Richard J Honeywell, Marie Maulandi, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 28, 2021
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study
Clémence Marin, Nihel Khoudour, Aurélien Millet, et al.
Cancer Chemotherapy and Pharmacology
|
November 13, 2023
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
Mourad Hamimed, Raynier Devillier, Pierre-Jean Weiller, et al.
Cancer Chemotherapy and Pharmacology
|
December 25, 2008
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile
Cedric Mercier, Charlotte Dupuis, Aurore Blesius, et al.
Clinical and Translational Science
|
February 15, 2020
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer
Clémence Marin, Anis Krache, Chloé Palmaro, et al.
Pharmacogenomics
|
September 6, 2019
Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency
Crescent C Gbeto, Sylvie Quaranta, Roxane Mari, et al.
Page
of 17